Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Gyre Therapeutics, Inc. (GYRE) had Normalized Pre-Tax Income of $-9.24M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$22.52M |
|
$-8.69M |
|
$1.23M |
|
$21.29M |
|
$31.87M |
|
$-9.36M |
|
$0.12M |
|
$-9.24M |
|
|
Normalized Pre-Tax Income |
$-9.24M |
$-9.86M |
|
$-9.86M |
|
$-9.86M |
|
$-9.86M |
|
$-9.36M |
|
$-8.68M |
|
91.32M |
|
91.34M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$91.73M |
|
$23.57M |
|
$70.28M |
|
$162.01M |
|
$19.79M |
|
-- |
|
$5.24M |
|
$25.03M |
|
$136.99M |
|
$132.36M |
|
$136.99M |
|
91.34M |
|
| Cash Flow Statement Financials | |
$3.18M |
|
$-3.06M |
|
$0.02M |
|
$37.07M |
|
$37.50M |
|
$0.43M |
|
$2.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.64 |
|
-- |
|
-- |
|
-- |
|
-- |
|
94.55% |
|
-41.54% |
|
-41.54% |
|
-- |
|
-41.02% |
|
-38.59% |
|
$3.01M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
0.11 |
|
0.98 |
|
91.89 |
|
-7.20% |
|
-7.45% |
|
-6.08% |
|
-7.20% |
|
$1.50 |
|
$0.03 |
|
$0.03 |
|